LAVAL, QC / ACCESSWIRE / October 20, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food ...

Please provide your email address to receive an email when new articles are posted on . IDP-126 — a combination of clindamycin, adapalene and benzoyl peroxide — reduced acne severity in about half of ...

Cabtreo combines clindamycin phosphate, a lincosamide antibacterial, adapalene, a retinoid, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic effects, into one topical gel.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 82.7% of patients treated with the triple combination ...

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin ...

LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health (BHC), Canada Inc., part of Bausch Health Companies Inc., today announced that Pr CABTREO TM (clindamycin phosphate, adapalene and benzoyl ...

Combined therapies have emerged as the key strategy in reducing the presence of resistant bacteria, while increasing the efficacy of treatment. Concomitant use of nonantibiotic therapies such as ...

ALLEGAN, Mich. Perrigo announced Tuesday that partner company Cobrek Pharmaceuticals filed a regulatory approval application for Evoclin foam. Perrigo said the application, for clindamycin phosphate ...

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health (BHC), Canada Inc., part of Bausch Health Companies Inc., a global, diversified pharmaceutical company, today announced that Pr CABTREO ™ ...